Our findings suggest EGFR inhibitors could serve as a promising therapeutic option for managing recurrent WT patients; however, further investigation is required to fully elucidate the mechanisms driving the upregulation of EGFR in Scissor+ tumor cells. The gene discussed is EGFR; the disease is neoplasm.